- Home
- UNP vs GILD Comparison
UNP vs GILD Comparison
Compare UNP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNP | GILD |
|---|---|---|
| Founded | 1862 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.9B | 184.4B |
| IPO Year | 2004 | 2000 |
Fundamental Metrics
Financial Performance| Metric | UNP | GILD |
|---|---|---|
| Price | $242.14 | $144.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 18 |
| Target Price | ★ $261.68 | $146.50 |
| AVG Volume (30 Days) | 2.8M | ★ 5.5M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.26% | 2.26% |
| EPS Growth | 8.03 | ★ 1684.21 |
| EPS | ★ 11.98 | 6.78 |
| Revenue | $19,533,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $4.22 | $4.68 |
| Revenue Next Year | $4.75 | $6.10 |
| P/E Ratio | ★ $20.34 | $21.44 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $204.66 | $95.30 |
| 52 Week High | $268.14 | $157.29 |
Technical Indicators
Market Signals| Indicator | UNP | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 48.65 |
| Support Level | $217.95 | $142.93 |
| Resistance Level | $268.14 | $157.29 |
| Average True Range (ATR) | 5.47 | 3.21 |
| MACD | -3.48 | -1.06 |
| Stochastic Oscillator | 6.46 | 27.44 |
Price Performance
Historical ComparisonAbout UNP Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24 billion of revenue in 2024 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).